FDA Warning Letters to Drug Manufacturers: Where They Go (2008–2026)
We analysed 732 FDA Warning Letters to drug manufacturers, issued 2008–2026, that we could attribute to a company in our directory. Enforcement is concentrated: 76% went to firms in the United States or India. These are not all FDA Warning Letters, so the counts describe where letters go, not how FDA activity has changed over time.
Edition of 23 October 2026 (first edition July 2026) · Source: U.S. FDA · Data and query · Analysis by PharmaTek Intelligence
Reviewed by Dr Sanaz Baheran, PhD in pharmaceutical science, co-founder of PharmaTek
Key findings
Two countries receive three in four letters
Of the 731 letters with a country in the FDA record, 58% went to firms in the United States and 18% to firms in India. China was third with 7%.
Counts by year are not an FDA trend
Our count for 2025 (80) and 2026 to date (85) is higher than earlier years, but we keep only letters we can attribute to a directory company, and the directory has grown. Use FDA's own Warning Letter archive for trend questions.
Check the record, whatever the country
India-based firms received the second-largest number of letters in this dataset. A low landed cost can carry regulatory risk that a supplier's brochure will not show, so check the record before qualifying any site.
Warning Letters by year
Letters attributed to directory companies, by year issued, 2008–2026. 2026 is a partial year (letters stored by 23 October 2026). Coverage grew over time, so heights are not comparable as a trend.
Lighter bar: 2026, a partial year.
Warning Letters by country
Top 10 countries by number of letters, using the country in the FDA record (of 731 letters with one).
Highlighted: India — the #2 source of FDA drug Warning Letters.
What this means for sourcing teams
A Warning Letter is the FDA's formal notice that a manufacturer has significant violations of current Good Manufacturing Practice — often the step before import alerts, consent decrees, or supply disruption. For a buyer, an open or recent Warning Letter at a candidate site is a material risk that no capability deck will surface.
The geography is the practical takeaway. Firms in the US and India received three in four of these letters, reflecting where FDA-facing drug manufacturing and inspections are concentrated. That doesn't make any single supplier a poor choice; it makes screening the regulatory record a non-negotiable step when you qualify a CDMO or API supplier — alongside an FDA Form 483 history and recall record.
PharmaTek screens its supplier directory against live FDA enforcement data — recalls, Warning Letters, and Form 483 observations — so these signals surface before you engage.
Methodology & sources
- Dataset: 732 FDA drug Warning Letters attributed by exact company name to a company in the PharmaTek directory, issued 2008–2026 (2026 partial: letters stored by 23 October 2026; FDA source last refreshed 12 October 2026). Letters we could not attribute are not stored, so this is not a census of FDA Warning Letters.
- Source: U.S. Food & Drug Administration compliance actions (openFDA and the FDA Warning Letters archive). Geography is the country recorded in the FDA letter record, not the company's headquarters. Letters are attributed by exact company name; after the 23 October 2026 link repair, a fresh review of 60 enforcement links found all of them attributed to the right legal entity (measured match quality).
- This analysis counts the volume and distribution of Warning Letters; it does not classify the underlying violations, and inclusion is not a judgement about any individual company.
Cite this report: PharmaTek Intelligence, “FDA Warning Letters to Drug Manufacturers: Where They Go (2008–2026),” edition of 23 October 2026. https://pharmatek.co.uk/reports/fda-warning-letters
Screen any supplier against live FDA enforcement data
Search recalls, Warning Letters, and Form 483 observations across thousands of drug manufacturers and API suppliers.
See the directory